Herantis Taps Spark Therapeutics Veteran as CMO to Advance Parkinson’s Drug
Event summary
- Herantis appoints Dr. Juha Savola as Chief Medical Officer, bringing 25+ years of drug development experience in neurology and gene therapy.
- Savola previously led clinical programs at Spark Therapeutics, including Parkinson’s disease and Huntington’s disease treatments.
- HER-096, Herantis’ lead candidate, is set to enter Phase 2 trials in 2027 after showing safety in a Phase 1b study.
The big picture
Herantis strengthens its leadership with a seasoned neurology expert as it prepares for pivotal trials in Parkinson’s disease. The hire underscores the company’s push toward regulatory milestones, critical for attracting partners or buyers in a competitive neurodegenerative space. Savola’s track record in gene therapy and rare diseases adds strategic depth to Herantis’ efforts to differentiate HER-096.
What we're watching
- Clinical Progress
- Whether HER-096 can demonstrate efficacy in Phase 2 trials, validating its disease-modifying potential.
- Regulatory Strategy
- How Savola’s experience with FDA and EMA engagements will shape Herantis’ global approval path.
- Partnering Dynamics
- The pace at which Herantis secures strategic collaborations to advance HER-096 beyond Phase 2.
Related topics